Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Viscoli, Catherine M. [VerfasserIn]   i
 Ringleb, Peter A. [VerfasserIn]   i
Titel:Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack
Titelzusatz:rationale and design of the Insulin Resistance Intervention after Stroke Trial
Verf.angabe:Catherine M. Viscoli, Lawrence M. Brass, Antonio Carolei, Robin Conwit, Gary A. Ford, Karen L. Furie, Mark Gorman, Peter D. Guarino, Silvio E. Inzucchi, Anne M. Lovejoy, Mark W. Parsons, Peter N. Peduzzi, Peter A. Ringleb, Gregory G. Schwartz, J. David Spence, David Tanne, Lawrence H. Young, Walter N. Kernan, on behalf of the IRIS Trial investigators
E-Jahr:2014
Jahr:28 July 2014
Umfang:13 S.
Teil:volume:168
 year:2014
 number:6
 pages:823-829.e6
 extent:13
Fussnoten:Gesehen am 09.11.2020
Titel Quelle:Enthalten in: American heart journal
Ort Quelle:Amsterdam [u.a.] : Elsevier, 1925
Jahr Quelle:2014
Band/Heft Quelle:168(2014), 6, Seite 823-829.e6
ISSN Quelle:1097-6744
Abstract:Background - Recurrent vascular events remain a major source of morbidity and mortality after stroke or transient ischemic attack (TIA). The IRIS Trial is evaluating an approach to secondary prevention based on the established association between insulin resistance and increased risk for ischemic vascular events. Specifically, IRIS will test the effectiveness of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class, for reducing the risk for stroke and myocardial infarction (MI) among insulin resistant, nondiabetic patients with a recent ischemic stroke or TIA. - Design - Eligible patients for IRIS must have had insulin resistance defined by a Homeostasis Model Assessment-Insulin Resistance >3.0 without meeting criteria for diabetes. Within 6 months of the index stroke or TIA, patients were randomly assigned to pioglitazone (titrated from 15 to 45 mg/d) or matching placebo and followed for up to 5 years. The primary outcome is time to stroke or MI. Secondary outcomes include time to stroke alone, acute coronary syndrome, diabetes, cognitive decline, and all-cause mortality. Enrollment of 3,876 participants from 179 sites in 7 countries was completed in January 2013. Participant follow-up will continue until July 2015. - Summary - The IRIS Trial will determine whether treatment with pioglitazone improves cardiovascular outcomes of nondiabetic, insulin-resistant patients with stroke or TIA. Results are expected in early 2016.
DOI:doi:10.1016/j.ahj.2014.07.016
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1016/j.ahj.2014.07.016
 Volltext: http://www.sciencedirect.com/science/article/pii/S0002870314004360
 DOI: https://doi.org/10.1016/j.ahj.2014.07.016
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1738223752
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68658805   QR-Code
zum Seitenanfang